The stock of Clarus Therapeutics Holdings Inc. (NASDAQ:CRXT) decreased by $0.0 on Tuesday to finish at $0.36, down -1.44 percent. The last five days have seen an average of 3,100,100 shares of common stock traded. 3 times new highs were reached in the current year, with a fall of -$2.0749. The average number of shares traded over the last 20 days was 4,960,100, while the average volume over the last 50 days totaled 16,852,213.
CRXT stock dropped -12.88% since last month. On 05/26/22, the company’s shares reached a one-month low of $0.3302. The stock touched a high of $31.24 on 04/20/22, after rallying from a low of $0.33 in 52 weeks. The price of CRXT stock has declined by -85.39% or -$2.0749 this year, reaching a new high 3 times. Still, the stock price is down -98.86% from the 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
For the three months ended March 30, Clarus Therapeutics Holdings Inc.’s quick ratio was 0.30, while its current ratio was 0.60, indicating its inability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 80.70% percent. Based on annual data, it had gross profit of $11.24 million and revenue of $13.96 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. There was a -141.00% return on investment (ROI) in the past year.
According to Clarus Therapeutics Holdings Inc.’s quarterly financial report for the quarter that ended March 30. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $4.01 million, while revenues rose by 100.0% to -$4.29 million. It was predicted that Clarus Therapeutics Holdings Inc.’s quarterly earnings would be -$0.61, but it ended up being -$0.4, beating the consensus by -52.50%. EBITDA was -$13.54 million for the quarter. At the end of Clarus Therapeutics Holdings Inc.’s most recent quarter ended March 30, its liabilities totaled 66.88 million, while its total debt was $38.48 million. Equity owned by shareholders amounts to $52.02 million.
Here’s a quick look at Clarus Therapeutics Holdings Inc.’s (CRXT) price momentum from a technical perspective. As of 21 June, the RSI 9-day stood at 34.76%, suggesting the stock is Neutral, with a 67.11% historical volatility rate.
The stochastic %K and %D were 5.22% and 8.79% respectively, while the average true range (ATR) was 0.0572. Based on the 14-day stochastic reading of 7.28%, the RSI (14) reading is 38.18%. On the 9-day MACD Oscillator, the stock is at -0.0200, and the 14-day reading is at -0.0580.
Analysts have assigned Clarus Therapeutics Holdings Inc. (CRXT) an Buy rating. CRXT is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 4 others recommend it as a buy.
What is CRXT’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.50 and $3.00, with a median target price of $3.00. In analyzing these forecasts, the average price target given by analysts for Clarus Therapeutics Holdings Inc. (CRXT) is $2.63.